Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.54 |
| ▸ | PPARD | Q03181 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HIPK4 | Q8NE63 | 3/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | FABP2 | P12104 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329127 | 0.95 | PPARA (0.56) | PPARAPPARDMEN1CYP1A2CYP3A4 | |
| SCHEMBL6328138 | 0.93 | PPARA (0.56) | PPARAPPARDHIPK4PPARG | |
| SCHEMBL6325562 | 0.92 | PPARA (0.55) | PPARAPPARDMEN1CYP1A2CYP3A4 | |
| SCHEMBL6333235 | 0.91 | PPARA (0.67) | PPARAPPARDMEN1CYP1A2CYP3A4 | |
| SCHEMBL6329096 | 0.90 | PPARA (0.56) | PPARAPPARDMEN1CYP1A2CYP3A4 | |
| SCHEMBL6328747 | 0.88 | PPARA (0.54) | PPARAPPARDMEN1CYP1A2CYP3A4 | |
| SCHEMBL6327988 | 0.88 | PPARA (0.51) | PPARAPPARDMEN1CYP1A2CYP3A4 | |
| SCHEMBL6334662 | 0.85 | PPARA (0.47) | PPARAPPARDMEN1CYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL6325797 | 0.84 | PPARA (0.49) | PPARAPPARDMAPT | |
| SCHEMBL6328831 | 0.84 | PPARA (0.57) | PPARAPPARDMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014805-A1 | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014805-A1 | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity | GPR119, EGLN3, PC | PPARA 49/4885PPARD 55/4885MEN1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.